Since CaMKIIβ-specific inhibitors are being developed for the treatment of cardiomyopathy [99], if they are able to cross the blood-brain barrier, it will be important to note their effects in patients who also have schizophrenia. This evidence concerns the gene CAMK2B and schizophrenia.